Оценка эффективности капецитабина при лечении отдаленных метастазов рака молочной железы
![Диссертация: Оценка эффективности капецитабина при лечении отдаленных метастазов рака молочной железы](https://westud.ru/work/2887219/cover.png)
Диссертация
Внедрение результатов исследования. Результаты проведенного исследования применяются при лечении больных раком молочной железы в Кировском областном онкологическом диспансере. Основные положения работы включены в лекционный курс и практические занятия на кафедре онкологии Государственного образовательного учреждения высшего профессионального образования «Кировская государственная медицинская… Читать ещё >
Содержание
- Глава 1. Обзор литературы
- 1. 1. Эпидемиология
- 1. 2. Химиотерапия первой линии местнораспространенного рака молочной железы 11 >
- 1. 3. Химиотерапия второй линии местнораспространенного и метастатического рака молочной железы
- 1. 4. Роль лучевой терапии в лечении рака молочной железы
- 1. 5. Роль гормонотерапии в лечении рака молочной железы
- 1. 6. Капецитабин (кселода): характеристика, фармакокинетика и эффективность
- Глава 2. Материалы и методы
- 2. 1. Характеристика исседования
- 2. 2. Характеристика больных
- Глава 3. Результаты исследования
- 3. 1. Оценка непосредственной эффективности лечения
- 3. 2. Оценка общей выживаемости
- 3. 3. Оценка общего состояния больных
- 3. 4. Оценка токсичности лечения
Список литературы
- Аксель Е.М., Давыдов М. И. Злокачественные новообразования в России и странах СНГ. // Вестник РОНЦ им. Н. Н. Блохина РАМН, Москва, 2003.
- Александров Н.Н., Муравская Г. В., Пантюшенко Т. А. Сравнительный анализ эффективности обычного и крупного фракционирования дозы при предоперационном облучении рака молочной железы // Вопр. онкол. -1981. Т. 27, № 7.-С. 3−8.
- Барканов А.И. Роль лучевой терапии в лечении рака молочной железы // Маммология. -1996. № 2. — С. 50−53.
- Возный Э.К., Бяхов М. Ю., Васюта Н. Ю., Мещерякова Н. Г. Неоадьювантная химиотерапия в комплексном лечении рака молочной железы// Сов. медицина. 1988. — № 10. — С. 96−99.
- Волкова М.А., Воскресенская Т. И., Коннова JI.B. Дистанционная гамма терапия в комбинированном лечении рака молочной железы // Вопр. онкол. — 1980.-Т. 26,№ 5.-С. 3−9.
- Гарин A.M., Хлебнов А. В. Справочник практической химиотерапии опухолей. Москва, 1995, 309 с.
- Даценко B.C. Эволюция методик предоперационной лучевой терапии при раке молочной железы // Вопр. онкол. -1990. Т. 36, № 12. — С. 1448−1454.
- Демидов В.П., Борисов В. И., Иванов О. А. Сравнительный анализ методов комбининованного и комплексного лечения рака молочной железы Шб стадии // Вопр. онкол. 1990.- Т. 36, № 12. — С. 1473−1479.
- Доненко Ф.В. Резистентность опухолей к проводимому лечению и пути ее преодоления: Дисс. д-ра мед. наук. М., 1994 291с.
- Изотова И. А. Комбинированное и комплексное лечение локализованных и местнораспространенных форм рака молочной железы: Дисс.. д-ра мед. наук. Обнинск, 1991.- 322 с.
- Кушлинский Н.Е., Герштейн Е. С. Современные возможности молекулярно-биохимических методов оценки биологического «поведения» рака молочной железы. // Вестник РАМН. — 2001.-С .65−70.
- Левина Е.С. Комбинированное лечение рака молочной железы П-Ш стадий: Автореф. дис. канд. мед. наук. Томск, 1987.- 23 с.
- Моисеенко В.М., Семиглазов В. Ф., Тюляндин С. А. Современное лекарственное лечение местно-распространенного и метастатического рака молочной железы. // Санкт-Петербург, 1997. 254 с.
- Моисеенко В.М. Алгоритм выбора терапии. I, II, III линий терапии. // Практическая онкология. 2000. — № 2. — С. 22−25.
- Муравская Г. В., Милевская Т. Г. Применение нетрадиционного режима облучения при раке молочной железы // Здравоохранение Белоруссии. -1989. -№ 4.-С. 47−50.
- Н.Ф. Орел. Рак молочной железы /Руководство по химиотерапии опухолевых заболеваний под ред. Н. И. Переводчиковой. М.: Практическая медицина, 2005 С. 265.
- Орлова Р.В. Принципы лекарственного лечения больных диссеминированным раком молочной железы. // Практическая онкология. 2000. — № 2. — С. 19−21.
- Павлов А.С., Даценко B.C. Роль лучевой терапии при хирургическом лечении больных раком молочной железы // Вопр. онкол. -1987.-Т. 33, № 3. С. 40−45.
- Павлов АС, Даценко B.C. Эволюция лучевой терапии при раке молочной железы // Мед. радиология. 1989. — Т. 34, № 8. — С. 27−31.
- Переводчикова Н.И. Терапия метастатических (диссеминированных) форм рака молочной железы //В сб.: Новое в терапии рака молочной железы / Под ред. Н. И. Переводчиковой. — М—1998.— С53−67.
- Поляков П.Ю., Коршунов А. И., Ларионова Н. А. и др. Нетрадиционные подходы к лучевому лечению онкологических больных // Вопр. онкол. 1997. Т. 43, № 5. — С. 487−492.
- Семиглазов В.Ф. Значение прогностических и предсказывающих факторов при выборе лечения у больных метастатическим раком молочной железы. // Практическая онкология. 2000. -№ 2. — С. 26−30.
- Соколова В.Д. Опыт применения различных противоопухолевых препаратов и их комбинации при раке молочной железы: Автореф. дис.. канд. мед. наук.- М., 1971 .-22 с.
- Тюляндин С.А. Химиотерапия диссеминированного рака молочной железы. // Практическая онкология. — 2000. № 2. — С. 3−9.
- Харченко В.П., Хмелевский Е. В., Панышш Г. А. Роль современной лучевой терапии в лечении местнораспространенного рака молочной железы // Материалы 1 съезда онкологов стран СНГ.- М., 1996. Ч. 2.-С. 616.
- Химиотерапия опухолевых заболеваний. Краткое руководство. Под редакцией, проф. Н. И. Переводчиковой. Москва, 2000. 391 с.
- Чиссов В.И. Состояние онкологической помощи населению России в 2005 г. М.: ФГУ МНИОИ им. П. А. Герцена Росздрава, 2006. 186 с.
- Шомова М.В. Местно-распространенный рак молочной железы: автореф. дисдок. мед. наук. М., 1999. — 40 с.
- Agostara B- Gebbia V- Testa A- et al Mitomycin С and vinorelbine as second line chemotherapy for metaststic breast carcinoma. // Tumori. 1994. — V. 80, N1.-P. 33−6.
- Ahera V., Barraclough В., Bosch С., Langlands A., Boyages J. Locally advanced breast cancer- defining an optimum treatment regimen. // Int. J. Radiat. Oncol. Biol. Phys. -1994.- Vol. 28, № 4.- P. 867−75.
- A’Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. // Br J Cancer. 1993.-N67.-P. 801−805.
- Ahmann DI, Bisel HP Hahr RG- Phase 2 clinical trial of ifosfamide (NSC-109 724) in patients with advanced breast cancer. // Cancer Chemother Rep. 1974.-P, 861−65.
- Aryus B, Audretsch W, Gogolin F, Gripp S, Konigshausen T, Lammering G, Rohn R, Hartmann KA. Remission rates following preoperative chemotherapy and radiation therapy in patients with breast cancer. // Strahlenther Onkol. — 2000. V. 176, N9.-P. 411−5.
- Baltaly E, Guler N, Ozisik Y, et al. Navelbine and Mitomycin combination as salvage chemotherapy in metastatic breast cancer. // Ann of Oncol. 21stCongress oftheESMO. 1996.- V. 7 (suppl 5). — abstr 143.
- Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer. // World J Surg Oncol. 2004. — V. 20, N 2 (1). — P. 16.
- Bedwinek J., Rao V.D., Perez C., Lee J., Fineberg B. Stage Ш and localized stage IV breast cancer: irradiarion alone vs irradiation plus surgery // Int. J. Radiat. Oncol. Biol. Phys. 1982. -Vol. 8. — P. 31−36.
- Bellmunt J, Morales S, Navarro M and Sole L-A .Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines Cancer Chemother // Pharmacol. 1990. — N 26 (suppl). -P. S81-S84.
- Bland KI, Fuchs A, Wittliss JL. Menopausal status as a factor in the distribution of estrogen and progestin receptors in breast cancer. 37th Annual Meeting of the Forum on Fundamental surgical Problems. // Surg Forum. — 1981. N 32.-P. 410−412.
- Bloom H, Richardson W, Harries E. Natural history of untreated breast cancer (1805−1933). // Br Med J. 1962. — V. 2.
- Blum JL, Buzdar AU, Dieras V et al. A multicenter phase II trial of Xeloda™ (capecitabine) in taxane-refractory metastatic breast cancer. // Proc Am Soc Clin Oncol. 1999. — N 18. — P. 107a.
- Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. // J Clin Oncol. -1999.-N 17.-P. 485−493
- Booser DJ, Walters RS, Holmes FA, Hortobagyi GN. Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsedmetastatic breast cancer: a phase II study. // Am J Clin Oncol. 2000. — V. 23, N l.-P. 40−1.
- Bromberg C- Remick S- Нафег G- et al. Concurrent 72-hour continuous infusion (CI) of etoposide (VP-16) and cisplatin (DDP) in metastatic breast cancer (abstract) // Proc Annu Meet Am Soc Clin Oncol. 1991. — N 10. -P. A70.
- Bruno S, Lira-Puerto V, Texeira L et al. Phase 2 trial with navelbine in the treatment of advansed breast cancer patients.Abstract.// Ann. Oncol. 1992. -N 3 (Suppll). -P. 126 (abstr 268a).
- Buchanan RB, Blarney RW, Durrant KR, et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. // J Clin Oncol. 1986. — N 4. — P. 1326−130.
- Budman DR, Meropol NJ, Reigner В et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. // J Clin Oncol. 1998. — N 16.-P. 1795−1802.
- Buzdar AU. Current developments in hormonal therapy of breast cancer. // Clin Breast Cancer. 2004. — N 5, Suppl l.-P. S4−5.
- Cals L, Nouyrigat P, Valenza B, Pedinelli FJ, Juin P. Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase 1Л1 study. // Oncology. 2004. — V. 67, N (3−4). -P. 257−61.
- Campbell C, Ragaz J, Plenderleith IH, et al. Phase 1−2 trial of long term 5FU infusion in the palliative therapy of metastatic breast cancer.Abstract. // Proc. of ASCO. 1995. — P. 14 (abstr.247).
- Campora E, Gardin G, Gasco M, et al. Does palliative therapy really palliate? //Proc ASCO. 1996. -N. 15. — P. 96.
- Cao S, Lu K, Ishitsuka H et al. Antitumor efficacy of capecitabine against fluorouracil-sensitive and resistant tumors. // Proc Am Soc Clin Oncol. -1997.-N 16.-P. 226a
- Cassidy J, Dirix L, Bissett D. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. // Clin Cancer Res. 1998. -N 4. -P. 2755−2761
- Ceilley E, Jagsi R, Goldberg S, Grignon L, Kachnic L, Powell S, Taghian A. Radiotherapy for invasive breast cancer in North America and Europe: Results of a survey. // Int J Radiat Oncol Biol Phys. 2005. — V. 61, N 2. — P. 36 573.
- Chang AY, Hui L, Asbury R, Boros L, Garrow G, Rubins J. Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. // Cancer Chemother Pharmacol. 1999. — N 44, Suppl. — P. S26−8.
- Chehal A, Taher A, Khalil M, Shamseddine A. Cisplatin plus vinorelbine (PVn) as a salvage regimen for refractory breast cancer. // Breast. — 2004. V. 13, N5.-P. 421−4.
- Citron ML. Dose density in adjuvant chemotherapy for breast cancer. // Cancer Invest. 2004. — V. 22, N 4. -P. 555−68.
- Clark GM, Sledge GW, Osborne CK, Mcuire WL. Survival from first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients.//J Clin Oncol. 1987.-N5.-P. 55−61.
- Coppola F- Balbiani L- Blajman C- et al Vinorelbine (VNB) containing regimen in three different schedules for the treatment of advanced breast cancer (ABC). // Proc Annu Meet Am Soc Clin Oncol. 1994. — N 13. -P. A144.
- Crown J- Hakes T- Reichman B- et al. Phase II trial of carboplatin and etoposide (VP 16) in metastatic breast cancer (abstract) // Proc Annu Meet Am Soc Clin Oncol. 1992.-N ll.-P. A179.
- Davidson K, Cameron DA, Dillon P, Bowman A, Stewart M, Leonard RC. Locally advanced breast cancer: the outcome of primary poly chemotherapy based on infiisional 5 fluorouracil. // Breast. 1999. — V. 8, N 3. — P. 110−5.
- Dechant KL- Brogden RN- Pilkington T- Faulds D Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic propeties and its therapeutic efficacy in cancer // Drugs. 1991. — V. 42, N 3. — P. 428−67.
- Degardin M, Bonneterre J, Hesquet B, Pion JM, et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. // Ann Oncol. 1994. — V. 5, N 5. — P. 423−6.
- DeVita V, Hellman S, Rosenberg S (eds). Cancer: Principles and Practice of Oncology. Philadelphia, JB Lippincott, 1989.
- DeVita V, Hellman S, Rosenberg S (eds): Cancer: Principles andiL
- Practice of Oncology. 4 edit. Lippincott Co, Philadelphia, 1993.
- Dinota A, Bilancia D, Romano R, Manzione L. Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer. // Breast Cancer Res Treat. 2005. — V. 89, N 1. — P. 1−3.
- Dooley M, Goa KL. Capecitabine. // Drugs. 1999. — V. 58, N 1. — P.69.76.
- Doroshow JH, Leong I, Margolin K, et al. Refractory metastatic breast cancer: salvage therapy with fluorouracil and high dose continuous-infusion leucovorin calcium. // J Clin Oncol. 1989. — N 7. — P. 439−44.
- Endo M, Shinbori N, Fukase Y et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. // Int J Cancer.- 1999.-N83.-P. 127−134.
- Englesman E, Persijn JP, Korsten CB, Cleton FJ. Oestrogen receptors in human breast cancer tissue and response to endocrine therapy. // Br Med J. — 1973.-N 2.-P. 750−752.
- Faneyte IF, Kristel PM, van de Vijver MJ. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. // Anticancer Res. 2004. — V. 24, N 5A. — P. 2931−9.
- Fernandez Hidalgo O- Gonzalez F- Gil A- Campbell W- Barrajon E- Lacave AJ. 120-hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer // Am J Clin Oncol. -1989. -N 5. P. 397−401.
- Fine S, Erlichman C, Kaiser I, et al. Phase 2 trial of 5-FU and folinic acid for metastatic breast cancer. // Proc Am Clin Oncol. 1988. — N 7. — P. 41.
- Formenti S.C., Symmans W.F., Volm M., Skinner K., Cohen D., Spicer D., Danenberg P.V. Concurrent paclitaxel and radiation therapy for breast cancer // Semin. Radiat. Oncol.- 1999.-Vol. 9 (2 Suppl 1).- P. 34−42.
- Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31 510 women. // J Clin Oncol. 1998. — N 16. — P. 3439−3460.
- Fountzilas G- Skarlos D- Theoharis D- Giannakakis T- Stathopoulos G Carboplatin and oral etoposide in the treatment of patients with advanced breast cancer refractory to anthracyclines. // Tumori. 1993. — V. 79, N 6. — P. 389−92.
- Fowble B. Postmastectomy radiation: then and now // Oncology Huntingt-1997. Vol. 11, № 2.-P. 213−34.
- Francini G- Petrioli R- Aquino A- Gonnelli S Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitimycin C. // Cancer Chemother Pharmacol. 1993. — V. 32, N 5. — P. 359−64.
- Fumoleau P., Delgado FM, Delosier T, Monnier A, et al. Phase 2 trial of weekly intravenous vinorelbine in first line advansed breast cancer chemotherapy. // J. Clin Oncology. 1993. — N 1. — P. 1245−52.
- Gacko M, Gardin G, Campora E, et al. Efficacy of salvage therapy after failure of first-line chemotherapy for metastatic breast cancer (abstract).
- Gad-El-Mawla N, Hamza MR,. Zikri ZK, et al. Ifosfamide, methotrexate and 5-fluorouracil: effective combination resistant breast cancer // Cancer Chemother Pharmacol. 1990. — N 26 (Suppl.). — P. S 85 — S 86.
- Gale KE, Andersen JW, Tormey DC, et al: Hormonal treatment for metastatic breast cancer: An Eastern Co-operative Oncology Group phase III trial comparing aminoglutethimid to tamoxifen. // Cancer. 1994. N 73. — P. 354−361.
- Garcia-Conde J, Lluch A, Martin M et al. Phase 2 trial of weekly IV navelbine in first line advansed breast cancer chemotherapy. // Ann. Oncol. — 1994. -V. 5, N9.-P. 854.
- Gasparini G, Caffo O, Barai S, Frontini L, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase 2 study. //J Clin Oncol. 1994. -N 12 (10). -P. 20 994−101.
- Goldhirsh A, Gelber RD. Endocrine therapies in breast cancer. // Seminars in Oncology. 1996. — V. 23, N 4. — P. 494−505.
- Goldin A. Ifosfamide in experimental tumor systems. Semin Oncol 1982- 4: 14−23- R Becher, H Hofeler, О Kloke. Ifosfamide, memotrexate and 5-fluorouracil for pretreated advanced breast cancer. // Oncology. — 1991. — V. 48. -459−463.
- Graff C, Manente P, Stocker J, et al. A randomized phase 2 trial of two different schedules of mitomycm с and vinorelbine in pretreated breast cancer, abstract). // Ann of Oncol. 21st Congress of the ESMO. 1996. — V. 7. — P. 27, abstr 117P.
- Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer Statistics, 2001.11С. A. Cancer J. Clin. 2001. — N 51. — P. 15−36.
- Gregory WM, Smith P, Richard MA, et al.: Chemotherapy of advanced breast cancer: outcome and prognostic factors. // Br. J. Cancer. —1993. -N68.-P. 988−95.
- Hainsworth JD, Andrews MB, Johnston DH. Mitoxantrone fluorouracil and high dose leucovorin. An effective, well-tolerated regimen for metastatic breast cancer. //J Clin Oncol. 1991. — N 9. — P. 1731−35.
- Hansen R, Quebbeman E, Beatty P. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. // Breast Cancer Res Treat. 1987. -N 10.-P. 145−9
- Harris JR, Morrow M, Bonadonna J. Cancer of the breast. In De Vita T Jr, Hellman S, Rosenberg SA (eds): Cancer Principle and Practice of Oncology. 4th edition. Philadelphia: JB Lippincot Co. — 1993. — P. 1264−332.
- Hart L- Chua C- Brophy L Savage chemotherapy for metastatic breast canrcinoma using cisplatin, fluorouracil and leucovorin: a phase I-II study (abstract) // Proc Annu Meet Am Soc Clin Oncol. 1989. -N 8. — P. A166.
- Henderson C. Endocrine Therapy of metastatic breast cancer. Chemotherapy for metastatic breast cancer. In: Breast diseases. Ed. By J Harris et al. 2nd edit. Lippincott Company. 1991. — P. 559−665.
- Hoeter-Janker H, Scheef W, Guenther U. Erfarungen mit der traktionierten Ifosfamid Stosstherapie bei generalisierten malignen Tumoren. // Med Welt. 1975. — N 20. — P. 972.
- Holmes FA, Walters RS, Theriault RL et al: Phase 11 trial of Taxol, an active drug in the treatment of metastatic breast cancer. // J Natl Cancer Inst. — 1991.-N83.-P. 1795−1805.
- Hortobagyi G, Ames F.C., Buzdar A.U. et al. Management of stage HI primary breast cancer with primary chemotherapy, surgery, and radiation therapy // Cancer.- 1988.- Vol. 62, № 12.- P. 2507−2516.
- Hortobagyi GN Mitomycin: its evolving role in the treatment of breast cancer. // Oncotogy. 1993. — N 50 (Suppl 1). — P. 1−8.
- Hortobagyi GN, Pivot X, Asmar L. Anthracycline-Resistant Breast Cancer. // Breast Cancer. 1997. — V. 25, N 4 (4). — P. 221−227.
- Hortobagyi GN. Summary of clinical results of vinorelbine (Navelbine)in the treatment of breast cancer. // Breast cancer. Advances in biology and therapeutics. F. Calvo,.M.Crepin, H. Magdelenat, (eds)John Libbey Eurotext. 1996. — P. 251−256
- Horton J. Management principles. // Cancer Control. 1999. — N 6. — P. 4−6.
- Huan S- Pazdur R- Smghakowinta A- Samal B- Vaitkevicius VK. Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. // Cancer. 1989. — V. 63, N 3. — P. 419−422.. .
- Hunt K.K., Ames F.C., Singletary S.E., Buzdar A.U., Hortobagyi G.N. Locally advanced noninflammatory breast cancer. // Surg. Clin. North. Am.-1996.- Vol. 76.- № 2.-P. 393−410
- Hunter H, Harrison EF- The anticancer spectrum of ifosfamide. I I Semin Oncol. 1982.-N 4.-P. 96−100.
- Icli F- Gunel N- Dincol D- Karaoguz H- Demirkazik A Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer. // J Surg Oncol. 1992. — V. 50, N 4. — P. 251−3.
- Ikeda T, Jinno H, Kitajima M. The evolution of primary chemotherapy in breast cancer treatment. // Breast Cancer. 2004. — V. 11, N 2. -P. 148−55.
- Ingle JN, Krook JE, Green SJ, et al. Randomized trial of bilateral oophorectomy vs tamoxifen in premenopausal women with metastatic breast cancer. // J Clin Oncol. 1986. — N 4. — P. 178−185.
- Jabboury K, Holmes F, Teriault R et al, Fluorouracil lenge by protracted continuous infusion in refractory breast cancer. // Proc Am Clin Soc Oncol. 1988,-N 7.-P. 39.
- Jacquillat C., Baillet F.5 Auclerc G., et al. Neoadjuvant chemotherapy of breast cancer //Drugs Exp. Chn. Res.-1986.-Vol. 12, № 1−3.-P. 147−52.
- JacquillatC., WeilM., Baillet F. et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer // Cancer.-1990.- Vol. 66, № 1.-P. 119−129.
- Jensen EV, DeSombe ER. Steroid hormone binding and hormone receptors. // Cancer Medicine. 1997. — P. 1049−1059.
- Jolivet J- Belanger K- Yelle L- et al The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast bancer. // Eur J Cancer. 1994. — V. 30A, N 5. — P. 626−8.
- Judson IR, Beale PJ, Trigo JM et al. A human capecitabine excretion balance and pharmaco-kinetic study after administration of a single oral dose of 14C-labelled drug. // Invest New Drugs. 1999. — N 17. — P. 49−56
- Kaufmann M, Jonat W, Kleeberg U, et al. Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. // J Clin Oncol. 1989. — N 7. — E: 11 131 119.
- Kellokumpu-Lehtinen P, Lantto A, Kokko R, Elomaa L, Jarvenpaa R, Lehtinen R, Blomqvist C. Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer. // Int J Clin Pharmacol Res. — 2002. — V. 22, N 2. — P. 4753.
- Klaassen U, Dlergarten K, Dinrick CH et al: Randomized trial of two doses of Taxol in metastatic breast cancer. // Onkologje. — 1994. N 17. — P. 8690.
- Kurtz J.M. Radiotherapy in the curative treatment of breast caancer: current status and future trends. // Radiother. Oncol.-1994.- Vol. 32.- P. 21−28
- Leonard RCF, Rodger A, Dixon JM. Metastatic breast cancer. // BMJ. 1994.-P. 309.
- Li N, van Agthoven M, Willemse P, Uyl-de Groot C. A cost—utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer. // Anticancer Drugs. 2001. — V. 12, N 6. — P. 533−40.
- Loprinzi CL- Krook JE- Schaid DJ- et al. Cisplatin plus etoposide (VP 16) in metastatic breast cancer: a phase II trial of the North Central Cancer Treatment Group. // Proc Annu Meet Am Soc Clin Oncol. N 8. — P. Al 59,1989.
- Mackean M, Planting A, Twelves С et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. // J Clin Oncol. 1998. — N 16. — P. 29 772 985.
- Malstrom P, Engellau G, Sugurdsson H. МММ as second-line treatment for advanced breast cancer. Evidence of cross-resistance with anthracyclines. // Eur J Cancer. 1993. — V. 29A, suppl. 6. -P. S84, abstr.441.
- Marini G, Simonchine E, Zanibody A, et al. 5-Fluorouracil and hogh dose folinic acid as salvage treatment of advanced breast cancer: an update. // Oncology. 1987. — N 44. — P. 336−40.
- Martin M, Lluch A, Casado A et al, Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. // J Clin Oncol. 1994. -N 12.-P. 986−991.
- Marty M, Leandri S, Extra JM, et al. A Phase 2 study of vinorelbine in patients with advansed breast cancer (Abstract) // Proc Amer Assoc Cancer Res. — 1989. N 30. — P. 256 (abstr 1017).
- Matsuoka T, Nomizu T, Yabuta T, Katagata N, Watanabe F, Yamaki Y, Tsuchiya A, Takenoshita S. Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer. // Gan To Kagaku Ryoho. 2000. — V. 27, N 7. — P. 1051−1055.
- Meza LA, Amin B, Hill T et al. Capecitabine plus paclitaxel as first-or second-line therapy: a multicentre phase II study in metastatic breast cancer. // Breast Cancer Res Treat. 2001. -N 69. — P. 271a.
- Mick R, Begg CB, Antman KH, et al. Diverse prognosis in metastatic breast cancer: who should be offered alternative therapies? // Breast Cancer Res Treat. 1989.-N13.-P. 33−38.
- Mitsumori M, Hiraoka M, Kodama H. Long-term Results of Postoperative Prophylactic Nodal Irradiation for Node-Positive, High-Risk Breast Cancer Patients. // Breast Cancer. 1999. — V. 6, N 3. — P. 193−200.
- Miwa M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5- fluoruracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. //Eur J Cancer. 1998. — N 34. — P. 1274−81
- Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferrau F, Zagonel V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini
- Murad AM, Tinoco LA, Schwartsmann G Phase 2 trial of the use of Taxol (T) and Ifosfamide (I) in heavily pre-treated patients with metastatic breast cancer (MBC). // 23rd Meeting of the American Society of Clinical Oncology. -1996, abstr. 52.
- Nabholtz JM, Reese DM, Lindsay MA, Riva A. Combination chemotherapy for metastatic breast cancer. // Expert Rev Anticancer Ther. — 2002. -V. 2, N2.-P. 169−80.
- O’Jones SE, Mennel RG, Brookes B. Phase 2 study of mitoxantrone, leucovorin and infiisional fluorourasil for treatment of metastatic breast cancer. // J Clin Oncol. 1991. — N 9. — P. 1736−39.
- Olson J.E., Neuberg D., Pandya K. J., et. al. The role of radiotherapy inthe management of operable locally advanced breast carcinoma: results of arandomized trial by the Eastern Cooperative Oncology Group // Cancer.-1997.-Vol. 79, № 6.-P. 1138−49.
- O’Reilly SM, Moiseyenko V, Talbot DC et al. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy. // Proc Am Soc Clin Oncol. 1998. — N 17. — P. 163a.
- O’Shaughnessy J, Moiseyenko V, Bell D et al. A randomized phase II study of XelodaIM (capecitabine) vs CMF as first line chemotherapy of breastcancer In women aged 55 years. // Proc Am Soc Clin Oncol. 1998. — N 17. — P. 103a.
- Patricio M.B., Pereira M.E., Ramos J., Neves M. Radioterapia do cancro avanfcado da mama.//Acta. Med. Port.-1993.-Vol 6, № 5.-181−186.
- Pazdur R. Phase II study ofUFt plus leucovorin in colorectal cancer. // Oncol. 1997. — V. 54 (suppl.l). — P. 19−23.
- Perrone F- De Placido S- Carlomagno C- et al. Mitomycin- С and mitoxantrone in anthracycline-preteated advanced breast cancer patients. A phase 2 study. // Am J din Oncol. 1994. — V. 17, N 3. — P. 218−22.
- Piccart M: Docetaxel: a new defence in the management of breast cancer. // Anticancer drugs. 1995. — suppl 4, N 6. — P. 7−11.
- Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. // Br J Cancer. — 2000. -V. 82, N3.-P. 529−34.
- Porkka K, Blomqvist C, Rissanen P, et al. Salvage therapies in woman, who fail to respond to first- line treatment with fluorouracil, epirubicin and cyclophosphamide for advanced breast cancer. // J. Clin Oncol. 1994. — V. 12, N8.-P. 1639−1647.
- Ravdin PM, Bums H, Fields SM, et al: Phase 2 evaluation of Taxotere (docetaxel, RP56796) as chemotherapy for doxorubicin or mitoxantrone refractory breast cancer. // Breast Cancer Res Treat. 1994. — N 32. — P. All.
- Reese T, Tanner J, Frings S et al. Capecitabine combined with simultaneous radiotherapy in rectal cancer: a phase-I-study. // Int J Radiat Oncol Biol Phys. 2000. — N 48 (suppl 3). — P. 120a.
- Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel (Taxol) and recombinant human granulocyte colony-stimulating factor as initional chemotherapy for metastatic breast cancer. // J. Clin. Oncol. — 1993. N 11. — P. 1943−1951.
- Robertson JFR, Lee D on behalf of the Arimidex study group. Statistic disease of long duration (>24 weeks) is an important remission criteries in breast cancer patients with the aromatase inhibitor anastrozole. // Eur J Cancer. — 1997. -N33.-P. 150.
- Rosso R, Del Mastro L, Durando A et al. Capecitabine in association with epirubicin and docetaxel as a first-line treatment in advanced breast cancer. // A multicenter phase II study. // Breast Cancer Res Treat. 2001. — N 69. — P. 270a.
- Rutqvist LE, Wallgen A. long-term survival of 458 young breast cancer patients. // Cancer. 1985. -N 55. — P. 658−665.
- Saphner T- Tormey DC- Albertini M- Winokur S Phase I trial of continuous infusion 5-FU with weekly bolus cis-platinum and etoposide (abstract) // Proc Annu Meet Am Soc Clin Oncol. 1991. — N 10. — P. A92.
- Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. // Clin Cancer Res. 1998. — N 4. — P. 1013−1019.
- Sawada N, Ishikawa T, Sekiguchi F et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (xeloda) in human cancer xenografts. // Clin Cancer Res. 1999. -N 5. — P. 2948−2953.
- Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. // Clin Cancer Res. — 1999. -V. 5, N 10.-P. 2948−53.
- Schnitker JN, Brock N, Burcert H, Fishtaer F. Ifosfamide bei malignen Tumoren. // Arzneimittelforchnung. 1976. — N 26. — P. 1783.
- Schuller J et al. Preferential activation of Capecitabine in tumor following oral administration in colorectal cancer patients. // Cancer Chemother Pharmacol, 2000.
- Seidman AD, Norton L, Reichman BS, et al: Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulatingfactor in the treatment of breast cancer. 11 Semin. Oncol. 1993. — (suppl 3), N 20. -P. 40−45.
- Shikama N, Oguchi M, Sone S, Arakawa K, et al. Radiotherapy following mastectomy: indication and contraindication of chest wall irradiation // Int. J. Radiat. Oncol. Biol. Phys.- 1999.-Vol. 44, № 5.- P. 991−6.
- Silva OE, Zurrida S. Breast cancer. A Guide for fellows. Presented by VeronesiU., 1999.
- Skinner KA, Dunnington G, Silberman H, Florentine В., Spicer D., Formenti S.C. Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer //Am. J. Surg.-1997.- Vol. 174, № 6.- P. 705−707.
- Sledge GW. First-Line Chemotherapy for advanced breast cancer. In: «Cancer Control». 1999.-N 6.-P. 17−21.
- Sledge GW: Etoposide in the mangement of metastatic brest cancer. // Cancer.-1991.-N .67.-P. 266−270. .
- Smith I.E., Jones A.L., O’Brien, McKirma J.A.- Sacks N., Baum
- Spaeth D- Conroy T- Krakowski I- Weber B- Luporsi E Cisplatin and long term continuous infusion of 5FU in advanced breast cancer: a retrospective study (abstract). // Ann Oncol. 1992. — N 3 (Suppl 5). — P. 85.
- Stein R, Coombes C, Howell A. The basis of hormonal therapy of cancer. In: Oxford Textbook of Oncology // Ed. M. Peckham et al. Oxford Medical Publication. 1995. — P. 629−648.
- Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. // J Clin Oncol. 1991. — N 9. — P. 1283.
- Surveillance, Epidemiology, and End Results (SEER) program, 1973 to 2000, Division of Cancer Control and Population Sciences, National Cancer Institute, 2003.
- Swain SM, Lippmann ME, Egan EF et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.,// J Clin Oncol. — 1989. V 7, N 7. — P. 890−9. • - ^ *
- Therialt RL, Hortobagyi GN, Kau Shu W, et al. Sequential multiagent chemotherapy in corporative cisplatin, doxorubicin and cyclophosphamide in the treatment of metastatic breast cancer. // Cancer. 1988. — N 62. — P. 2105−2110.
- Todd M, Shoan M, Cadman E. Survival of women with metastatic breast cancer at Yale from 1920 to 1980. // J Clin Oncol. 1983. — N 1. — P. 406 408.
- Tresca P, Fumoleau P, Roche R et al. Vinorelbine, a new active drag in breast carcinoma: results of an ART AC phase 2 trial Abstract. // Breast Can Res Treat. 1990.-N 16.-P. 123.
- Twelves CJ, Dobbs NA, Cumow’A, Coleman RE et al. A. phase/2, multicenter, randomizzed UK study of vinorelbine in advanced breast cancer. // Cancer. 1994.-V. 70, N5.-P. 990−3.
- Twelves C,' Glynne-Jones R, Cassidy5 J et al: Effect of hepatic. •' dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.//Clin Cancer Res. 1999.-N 5.-P. 1696−1702.
- Valavaara R. Reliability of estrogen receptors in predicting response to antiestrogens. // Oncology. 1997. — V. 11, N 5 (suppl. 4). — P. 14−18.
- Valero L, Walters RS, Theriault RL et al: Phase 11 trial of docetaxel (Taxotere) in anthracycline-refractory metastatic breast cancer (ARMBC). // Proc Am Soc CUn Oncol. 1994-N 13.-P. A 1636.
- Van Oosterom AT. Docetaxel (taxotere): an effective agent in the management of second-line breast cancer. // Semin Oncol. 1995. — N 22. — N 6 Suppl. 13.-P. 22−8.
- Venturini M, Del Mastro L, Garrone О et al. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. // Ann Oncol. 2002. — N 13. — P. 546 552.
- Verbeeck A. Bone metastases from breast cancer: guidelines for diagnosis. //J Manipulative Physiol Then- 2004. -V. 27, N3. -P. 211−5.
- Weber BL, Vogel C, Jones S, Harvey H, et al. Intravenous vinorelbine as first-line and second-line therapy in advansed breast cancer // J Clin Oncol. — 1995. V. 13, N 11.-P. 2722−30. —.. :•.' -.. ':: v
- Welt A et al. Capecitabine in". combination with- vinorelbiri in pretreated patients with metastatic breast cancer — Results of an extended phase II study Arm // Oncol. — 2002. — V. 56, Abst 202.
- Wils JA Mitoxantrone, leucovorin and high-dose incisional 5-fluorourasil: an effective and well-tolerated regimen for the treatment of advanced breast cancer. // Eur J Cancer. 1993 — V. 29A, N 15. — P. 2106−8.
- Winer EP, Morrow M, Osborne CK, Harris JR. Malignant tumors of the breast. In «Cancer: principles and practice of oncology». Edited by DeVita VT, Hellman S, Rosenberg SA. 6th edition, 2001, 1651−1726.
- Zheng H, Luo RC, You CX. Clinical observation of the efficacy of navelbine combined with ifosfamide and cisplatin in the treatment of advancedbreast cancer. // Di Yi Jun Yi Da Xue Xue Bao. 2003. — V. 23, N 10. — P. 10 889.